Price (delayed)
$1.16
Market cap
$36.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.38
Enterprise value
-$3,283
We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our
There are no recent dividends present for ACRV.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.